Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times
weekly to patients with advanced solid tumors or Non-Hodgkin's Lymphoma.